Thromb Haemost 2019; 119(09): 1481-1488
DOI: 10.1055/s-0039-1692426
Stroke, Systemic or Venous Thromboembolism
Georg Thieme Verlag KG Stuttgart · New York

Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis

Anders E. A. Dahm
1   Department of Haematology, Akershus University Hospital, Lørenskog, Norway
2   Institute of Clinical Medicine, University of Oslo, Oslo, Norway
,
Eva Marie Jacobsen
3   Department of Haematology, Oslo University Hospital, Oslo, Norway
,
Hilde Skuterud Wik
3   Department of Haematology, Oslo University Hospital, Oslo, Norway
,
Anne Flem Jacobsen
2   Institute of Clinical Medicine, University of Oslo, Oslo, Norway
4   Department of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway
,
Tom Eirik Mollnes
5   Research Laboratory, Nordland Hospital Trust, Bodø, Norway
6   Department of Clinical Medicine, UiT–The Arctic University of Norway, Tromsø, Norway
7   K.G. Jebsen TREC, UiT–The Arctic University of Norway, Tromsø, Norway
8   Department of Immunology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
9   Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, Trondheim, Norway
,
Sandip M. Kanse
10   Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
,
Per Morten Sandset
2   Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3   Department of Haematology, Oslo University Hospital, Oslo, Norway
› Author Affiliations
Funding This study was financially supported by grants from the Norwegian Research Council (grant no 160805-V50) and from the Eastern Health Authority Trust of Norway.
Further Information

Publication History

30 January 2019

24 April 2019

Publication Date:
29 June 2019 (online)

Abstract

High levels of complement C3 are associated with venous thrombosis (VT) in the general population. We investigated if high C3 and C4 levels were associated with pregnancy-related VT. We undertook the Norwegian VIP study, a case–control study of VT in pregnancy or within 3 months postpartum (cases, n = 313) and women without pregnancy-related VT (controls, n = 353). Determinants of C3 and C4 in the control women were investigated with linear regression and the odds ratio (OR) for pregnancy-related VT was calculated with logistic regression. We found that levels of C3 and C4 were associated with body mass index (BMI), C-reactive protein (CRP); with the coagulation factors (F) fibrinogen, FVIII, and FIX; and with the coagulation inhibitors antithrombin, protein C, protein S, and tissue factor pathway inhibitor. These associations were influenced by CRP levels. The crude OR for pregnancy-related VT was 1.8 (95% confidence interval [CI], 1.1–3.0) for C3 above the 90th percentile and 2.0 (95% CI, 1.2–3.2) for C4 above the 90th percentile. Stratification in antenatal and postnatal VT showed that C3 and C4 were only associated with postnatal VT with an OR for high C3 of 3.0 (95% CI, 1.8–5.0), and for high C4 of 2.6 (95% CI, 1.5–4.6). Adjustment for high FIX and BMI reduced the ORs. We conclude that the association between postnatal VT and C3 and C4 suggests that there is clinically relevant crosstalk between the complement and the coagulation system.

Authors' Contributions

A.D. did the statistics and wrote the first draft, A.F.J. collected the data and reviewed the manuscript, and P.M.S. designed the study and reviewed the manuscript. T.E.M. contributed intellectually with complement knowledge and interpretation of data. H.S.W., S.M.K., and E.M.J. edited the manuscript. All authors critically revised the manuscript and approved the final version.


Supplementary Material

 
  • References

  • 1 Cohen AT, Agnelli G, Anderson FA. , et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98 (04) 756-764
  • 2 Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol 2008; 198 (02) 233.e1-233.e7
  • 3 Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6 (04) 632-637
  • 4 Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 6 (06) 905-912
  • 5 Dahm AE, Bezemer ID, Bergrem A. , et al. Candidate gene polymorphisms and the risk for pregnancy-related venous thrombosis. Br J Haematol 2012; 157 (06) 753-761
  • 6 Hillmen P, Muus P, Röth A. , et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162 (01) 62-73
  • 7 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. ; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8 (11) 643-657
  • 8 Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol 2017; 178 (02) 181-195
  • 9 Barratt-Due A, Fløisand Y, Orrem HL. , et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford) 2016; 55 (07) 1337-1339
  • 10 Conway EM. Reincarnation of ancient links between coagulation and complement. J Thromb Haemost 2015; 13 (Suppl. 01) S121-S132
  • 11 Dobó J, Schroeder V, Jenny L, Cervenak L, Závodszky P, Gál P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol 2014; 61 (02) 69-78
  • 12 Høiland II, Liang RA, Hindberg K. , et al. Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism. Thromb Res 2018; 169: 50-56
  • 13 Huber-Lang M, Sarma JV, Zetoune FS. , et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12 (06) 682-687
  • 14 Foley JH, Walton BL, Aleman MM. , et al. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine 2016; 5: 175-182
  • 15 Amara U, Flierl MA, Rittirsch D. , et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 2010; 185 (09) 5628-5636
  • 16 Keshari RS, Silasi R, Lupu C, Taylor Jr FB, Lupu F. In vivo-generated thrombin and plasmin do not activate the complement system in baboons. Blood 2017; 130 (24) 2678-2681
  • 17 Howes JM, Richardson VR, Smith KA. , et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9 (03) 216-225
  • 18 Gushiken FC, Han H, Li J, Rumbaut RE, Afshar-Kharghan V. Abnormal platelet function in C3-deficient mice. J Thromb Haemost 2009; 7 (05) 865-870
  • 19 Subramaniam S, Jurk K, Hobohm L. , et al. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood 2017; 129 (16) 2291-2302
  • 20 Nørgaard I, Nielsen SF, Nordestgaard BG. Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen General Population Study. Clin Chem 2016; 62 (03) 525-534
  • 21 Ajjan R, Grant PJ, Futers TS. , et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 2005; 94 (05) 1048-1053
  • 22 Muscari A, Massarelli G, Bastagli L. , et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 2000; 21 (13) 1081-1090
  • 23 Bergrem A, Jacobsen EM, Skjeldestad FE, Jacobsen AF, Skogstad M, Sandset PM. The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study. Thromb Res 2010; 125 (05) e222-e227
  • 24 Bergrem A, Dahm AE, Jacobsen AF, Sandvik L, Sandset PM. Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism: a population-based case-control study. Thromb Haemost 2012; 108 (06) 1165-1171
  • 25 Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101 (11) 4387-4392
  • 26 Trigg DE, Wood MG, Kouides PA, Kadir RA. Hormonal influences on hemostasis in women. Semin Thromb Hemost 2011; 37 (01) 77-86
  • 27 Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Béguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85 (06) 1060-1065
  • 28 Butenas S, van't Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94 (07) 2169-2178
  • 29 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
  • 30 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345 (8943): 152-155
  • 31 van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95 (12) 3678-3682
  • 32 Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342 (10) 696-701
  • 33 Huber-Lang M, Ignatius A, Brenner RE. Role of complement on broken surfaces after trauma. Adv Exp Med Biol 2015; 865: 43-55
  • 34 Kanse SM, Gallenmueller A, Zeerleder S. , et al. Factor VII-activating protease is activated in multiple trauma patients and generates anaphylatoxin C5a. J Immunol 2012; 188 (06) 2858-2865
  • 35 van Griensven M, Ricklin D, Denk S. , et al. Protective effects of the complement inhibitor compstatin CP40 in hemorrhagic shock. Shock 2019; 51 (01) 78-87
  • 36 Derzsy Z, Prohászka Z, Rigó Jr J, Füst G, Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 2010; 47 (7-8): 1500-1506
  • 37 Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol 2011; 73: 503-514
  • 38 Copenhaver M, Yu CY, Hoffman RP. Complement components, C3 and C4, and the metabolic syndrome. Curr Diabetes Rev 2019; 15 (01) 44-48